Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant increase in stock price, rising over 35% recently and accumulating a total increase of over 1300% year-to-date, indicating strong market interest and potential investor confidence in the company's future prospects [1] Company Summary - As of the latest report, Beihai Kangcheng's stock is trading at 1.71 HKD with a trading volume of 30.39 million HKD [1] - The National Medical Products Administration approved the company's application for injectable Velaglucerase beta (brand name: Gorenin) on May 15, which is intended for long-term enzyme replacement therapy for patients aged 12 and above with Type I and III Gaucher disease [1] - The first prescription for Gorenin was issued on July 3, with the first patient receiving treatment at Xinhua Hospital [1] Industry Context - The founder and CEO of Beihai Kangcheng highlighted the challenges in financing treatments for rare diseases, noting that relying solely on basic national health insurance is insufficient for addressing patient payment difficulties [1] - The company is actively engaging with health insurance payment departments to establish a more feasible payment mechanism for rare diseases, aiming to pave the way for a better commercial environment for rare diseases in China [1]
港股异动｜北海康成-B(01228)再涨超35% 戈芮宁首张处方已落地 公司称正在积极与医保支付部门沟通